Literature DB >> 18317646

[Compliance to drug therapy in inflammatory bowel diseases outpatients from a university hospital].

Nathalie de Lourdes Souza Dewulf1, Rosane Aparecida Monteiro, Afonso Dinis Costa Passos, Elisabeth Meloni Vieira, Luiz Ernesto de Almeida Troncon.   

Abstract

BACKGROUND: Compliance to drug therapy is important for a successful treatment. Although many studies have assessed compliance to treatment in patients with chronic diseases, few investigations have been carried out in inflammatory bowel diseases. AIM: To assess compliance to drug therapy in patients with inflammatory bowel diseases, Crohn's disease and ulcerative colitis, followed at a university hospital, who had prescribed medication supplied by the Brazilian National Health System.
METHODS: In a cross sectional study, a structured interview was applied to assess the compliance of 26 Crohn's disease patients, 26 ulcerative colitis patients and 4 cases with undetermined colitis. Patients were characterized as presenting higher or lower degree of compliance, based on the comparison of the information provided by the patient in the interview and data in the medical records. The Morisky test was also used to assess the behavioral pattern of the patient regarding the daily use of the medication.
RESULTS: The interview showed that 15.4% of patients with Crohn's disease and 13.3% of those with ulcerative colitis could be regarded as less compliant. However, the Morisky test revealed lower compliance in 50% of patients with Crohn's disease and 63.3% of those with ulcerative colitis. Univariate analysis showed an association between low compliance and long disease duration, married status and colon involvement in Crohn's disease, and between low compliance and increased disease activity and greater number of medications in ulcerative colitis. However, multivariate analysis did not confirm any association between low compliance and any demographic or clinical factor.
CONCLUSIONS: A high degree of noncompliance to treatment, linked to habitual behavior and hard to predict from demographic or clinical factor, was detected in inflammatory bowel disease patients, which suggests the need for investment in patient education regarding medication use.

Entities:  

Mesh:

Year:  2007        PMID: 18317646     DOI: 10.1590/s0004-28032007000400003

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  5 in total

1.  The invisible pharmacist.

Authors:  Nathalie L S Dewulf; Vania dos Santos; Leonardo Regis Leira Pereira; Luiz E A Troncon
Journal:  Am J Pharm Educ       Date:  2009-07-10       Impact factor: 2.047

2.  INFLAMMATORY BOWEL DISEASES: CHARACTERISTICS, EVOLUTION, AND QUALITY OF LIFE.

Authors:  Caique Moraes Mendonça; Isaac José Felippe Correa Neto; Alexander de Sá Rolim; Laercio Robles
Journal:  Arq Bras Cir Dig       Date:  2022-06-17

3.  Self-reported treatment adherence in inflammatory bowel disease in Indian patients.

Authors:  Jay Bhatt; Samir Patil; Anand Joshi; Philip Abraham; Devendra Desai
Journal:  Indian J Gastroenterol       Date:  2009-11-24

4.  Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil.

Authors:  Luciana Resende Prudente; Juliana de Souza Diniz; Tatyana Xavier Almeida Matteucci Ferreira; Dione Marçal Lima; Nílzio Antônio Silva; Guylherme Saraiva; Erika Aparecida Silveira; Nathalie de Lourdes Souza Dewulf; Rita Goreti Amaral
Journal:  Patient Prefer Adherence       Date:  2016-05-19       Impact factor: 2.711

5.  Adherence to Medical Treatment in Inflammatory Bowel Disease Patients from a Referral Center in Bahia-Brazil.

Authors:  Laíla D Andrade; Fernanda A Oliveira; Victor D Mariano; Monique C A Santos; Fernanda A Pereira; Cláudia I N Dos Santos; Flora M L Fortes; Andrea M Pimentel; Jaciane A Mota; Neogélia P Almeida; Valdiana C Surlo; Bruno C Silva; Mila P Pacheco; Genoile O Santana
Journal:  Biomed Res Int       Date:  2020-09-26       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.